[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 50.16.107.222. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Letters
July 27, 2011

Clinical Inertia and Uncertainty in Medicine—Reply

Author Affiliations

Author Affiliations: Department of Geriatrics and Metabolic Diseases, Second University of Naples, Naples, Italy (dario.giugliano@unina2.it).

JAMA. 2011;306(4):383-384. doi:10.1001/jama.2011.1045

In Reply: Drs Mohan and Phillips focus on clinical inertia in the management of the diabetic patient. This is an area of expanding interest because in the United States, physicians can now choose a diabetes medication from no fewer than 10 pharmacologic classes, including the newest entries, the bile acid sequestrant colesevelam and quick-release bromocriptine. We agree that clinical inertia will remain an important problem, given the continuous evolution of clinical guidelines, and that physicians must interpret data and introduce treatments that benefit patients the most. However, the clinical benefit of intensifying drug therapy may be uncertain.

First Page Preview View Large
First page PDF preview
First page PDF preview
×